Data Sheet 6_Integrating CT radiomics and transcriptomics: a biologically-informed machine learning model for predicting chemotherapy response in advanced laryngeal cancer.xlsx

BackgroundPredicting response to induction chemotherapy (IC) in advanced laryngeal cancer (LC) remains a clinical challenge. This study aimed to develop a non-invasive, interpretable model integrating CT radiomics and clinical features to predict chemotherapy outcomes.
MethodsWe retrospectively analyzed 161 advanced LC patients treated with IC. From pre-treatment CT images, 1,321 radiomics features were extracted, and a radiomics score (Rad-score) was constructed using LASSO regression. Transcriptomic analysis explored the biological basis of Rad-score. Independent predictors were identified via multivariate logistic regression and used to build five machine learning models. Model performance was evaluated using AUC, accuracy, and specificity. SHAP analysis was applied to interpret the optimal model.
ResultsFour robust radiomics features were selected to construct the Rad-score. The Rad-score demonstrated satisfactory discrimination with an Area Under the Curve (AUC) of 0.715 in the training set and 0.707 in the validation set. In multivariate analysis, the Rad-score (Odds Ratio [OR]=2.89, 95% CI: 1.29–6.48, P = 0.010), gap invasion and validation were identified as independent predictors of chemotherapy response. Among the machine learning models, the Random Forest model achieved the best performance, yielding an AUC of 0.914 in the training set, 0.856 in the validation set, and 0.810 in the external test set. Decision curve analysis confirmed the clinical utility of the model. SHAP analysis confirmed Rad-score and fat space invasion as core predictors, with synergistic effects.
ConclusionsWe developed a highly accurate and interpretable Random Forest model that integrates radiomics and clinical features to predict IC response in advanced LC. This tool enables precise risk stratification and personalized treatment decisions, sparing non-responders from ineffective therapy. Prospective studies are needed to validate its clinical utility.